Shares of biotech company CureVac N.V. (CVAC) were in the spotlight on Thursday after the company’s fourth-quarter revenue fell below Wall Street estimates. The company reported a revenue of €14.5 ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for the open-label Phase I trial of CVHNLC in individuals with squamous ...

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 trial.

CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028.

CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

Greetings. Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my ...

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...